FCGR3A and neoplasm: NK cell therapy can be combined with immune checkpoint inhibitors to overcome tumor immune evasion and/or with monoclonal antibodies targeting tumor-specific antigens, thereby engaging CD16-mediated Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) to enhance antitumor efficacy (Fig. 1e) [28].